Company intelligence / Profile preview

Miami HEAT

Morrisville, North Carolina, United Statesnba.com ↗

Ownership: Private
Development stage: Other

Overview

Heat Biologics is a clinical-stage biopharmaceutical company developing immunotherapies using its proprietary gp96 platform. Its lead oncology asset HS‑110 is in Phase 2 trials for non-small cell lung cancer. The company has demonstrated positive preclinical results with its COVID‑19 vaccine candidate developed in collaboration with the University of Miami Miller School of Medicine. The gp96 platform has shown robust T-cell immune responses against SARS-CoV‑2 and other pathogens in animal models.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineCell therapyProteinSmall molecule
Industry: Biotech

Partnerships

University of Miami Miller School of MedicineNational Institutes of Health and Department of Defense research collaborations

Beyond the preview

Go deeper on Miami HEAT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miami HEAT.

Explore the full profile